BioElectronics Company Updates
Thursday, November 5, 2015
ActiPatch® Musculoskeletal Pain Therapy Market Expands Into 1,077 Lloyds Pharmacies, 186 Superdrug Pharmacies and 60 Gordons Chemist
“The Lloyds product placement and initial orders to stock these pharmacies are a substantial gain, but even more important long-term is the opportunity to work with the pharmacist to provide one-to-one consultation for chronic pain sufferers on the unique benefits and safety of ActiPatch” said Ben Fichter, Marketing Manager. “This is a great way to help patients discover how drug-free ActiPatch Therapy can help them manage their pain and restore daily activities while minimizing drug dependency.”
Superdrug is a subsidiary of the A.S. Watson Group, the world’s largest international health and beauty retailer with 12,000 stores. Superdrug will promote BioElectronics’ 7-Day Trial Device, Try & Tell Marketing Campaign online and stock ActiPatch in 186 stores in mid-November to create product demand on their web site,” said Ben Fichter, Marketing Director, BioElectronics Corporation. “We are looking forward to collaborating with this innovative retailer to extend our successful marketing program into the retail environment.”
Fichter explained that Superdrug will offer the 7-Day trial version of ActiPatch Therapy for about $5 US to attract new chronic pain customers. “Based on prior results using this marketing program, we expect the majority of consumers who buy the trial unit to later buy more than 2 full price units,” Fichter said. “The customer survey aspect of the program will help BioElectronics and Superdrugs marketing staff better understand the chronic pain management needs of consumers.” To date, the program has had exceptional consumer acceptance in reducing their pain and improving the quality of life.
Stu Taylor “On Business” Radio Interview with BioElectronics’ CEO Andrew Whelan November 5
Mr. Whelan reported on the exceptional acceptance the company’s flagship product ActiPatch Pain Relief Therapy, is achieving in the UK. Other topics for discussion include the US FDA market clearance application and Canada distribution progress.
To listen to the interview:
Chairman of BioElectronics Corporation Letter to Shareholders
Chairman Richard Staelin discusses sale and marketing of ActiPatch® in the United Kingdom and provides a Company update.
Read the full letter at www.bielcorp.com/bioelectronics-chairmain-letter-october-2015
Visit us at the U.S. Pavilion – Hall 16, Booth #: C18 (Maryland Booth) during the MEDICA Tradeshow in Dusseldorf, Germany on November 16-19, 2015.
MEDICA (www.medica.de) is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from well over 100 countries are expected to obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With the largest product display in the industry, MEDICA is the hub of the medical trade.
For complete details, please visit www.bielcorp.com/medica-tradeshow-2015
BioElectronics Social Media
Next Company Update: Thursday, December 3, 2015
To receive investor updates via e-mail, please contact us at IR@bielcorp.com with your name and e-mail address. Updates are posted every other Thursday. Thank you for your support!